Oncolytic immunotherapy of advanced solid tumors with a CD40L-expressing replicating adenovirus: assessment of safety and immunologic responses in patients.
about
Oncolytic viruses: finally deliveringEvidence for Oncolytic Virotherapy: Where Have We Got to and Where Are We Going?Immunostimulatory Gene Therapy Using Oncolytic Viruses as VehiclesOncolytic adenovirus-mediated therapy for prostate cancerTrial Watch:: Oncolytic viruses for cancer therapyVirotherapy: cancer gene therapy at last?Trial Watch-Oncolytic viruses and cancer therapyLatest developments in our understanding of the pathogenesis of mesothelioma and the design of targeted therapiesIL-33 induces nuocytes and modulates liver injury in viral hepatitis.Prime-boost using separate oncolytic viruses in combination with checkpoint blockade improves anti-tumour therapyOncolytic Immunotherapy: Conceptual Evolution, Current Strategies, and Future PerspectivesActivation of myeloid and endothelial cells by CD40L gene therapy supports T-cell expansion and migration into the tumor microenvironmentOncolytic immunotherapy: where are we clinically?Oncolytic adenovirus and doxorubicin-based chemotherapy results in synergistic antitumor activity against soft-tissue sarcoma.Classification of current anticancer immunotherapiesSerum HMGB1 is a predictive and prognostic biomarker for oncolytic immunotherapy.T-cell subsets in peripheral blood and tumors of patients treated with oncolytic adenoviruses.Case-control estimation of the impact of oncolytic adenovirus on the survival of patients with refractory solid tumorsChronic Activation of Innate Immunity Correlates With Poor Prognosis in Cancer Patients Treated With Oncolytic AdenovirusPotentiation of immunomodulatory antibody therapy with oncolytic viruses for treatment of cancer.Combinatorial treatment with oncolytic adenovirus and helper-dependent adenovirus augments adenoviral cancer gene therapy.Biodistribution Analysis of Oncolytic Adenoviruses in Patient Autopsy Samples Reveals Vascular Transduction of Noninjected Tumors and Tissues.Oncolytic adenovirus with temozolomide induces autophagy and antitumor immune responses in cancer patients.Trial watch: Oncolytic viruses for cancer therapyHSV-NIS, an oncolytic herpes simplex virus type 1 encoding human sodium iodide symporter for preclinical prostate cancer radiovirotherapyDendritic cells serve as a "Trojan horse" for oncolytic adenovirus delivery in the treatment of mouse prostate cancerCytokines for the treatment of gastrointestinal cancers: clinical experience and new perspectives.Targeting of the tumor necrosis factor receptor superfamily for cancer immunotherapy.Review of the impact of antineoplastic therapies on the risk for cholelithiasis and acute cholecystitis.Oncolytic vaccines.Oncolytic virus therapies.Adenoviruses as gene/vaccine delivery vectors: promises and pitfalls.In situ vaccination: Cancer immunotherapy both personalized and off-the-shelf.In situ vaccination for the treatment of cancer.Synergistic anti-tumor efficacy of immunogenic adenovirus ONCOS-102 (Ad5/3-D24-GM-CSF) and standard of care chemotherapy in preclinical mesothelioma model.Enhanced efficacy with azacytidine and oncolytic BHV-1 in a tolerized cotton rat model of breast adenocarcinoma.Oncolytic Immunotherapy for Treatment of Cancer.Intravenously usable fully serotype 3 oncolytic adenovirus coding for CD40L as an enabler of dendritic cell therapy.Recent advances in oncolytic adenovirus therapies for cancer.Tumor-specific oncolytic adenoviruses expressing granulocyte macrophage colony-stimulating factor or anti-CTLA4 antibody for the treatment of cancers.
P2860
Q26772039-E50DC79B-1F9C-4A5D-A336-0CB6E0CD8221Q26775030-5299F8B6-CE3F-4172-900B-445C6C560A5DQ26777403-A25A2069-66D8-48EF-A7DB-218342F1BF84Q27004796-573D0CB8-6C88-47FB-BD60-6515913A54DBQ27021951-A93A08C2-5850-430C-B631-330F718B7BF0Q28066228-BDCAD456-27E4-465C-B0C2-3D87FEF59420Q28072347-1C1270CE-9CD2-4AFC-B5A0-D08B7026A511Q28395597-A0B761CD-0BC8-4B9B-A4A0-4609B748C4F3Q28588039-47D3865D-1917-4D9D-ABE4-6162FB688554Q33551626-12A3E439-1996-4BBE-A50B-31C5E3106F21Q33679505-D3EFAD27-0FAE-4C60-9A2A-92D7CBC24BB7Q33718737-F3A12419-1B33-4A6D-B23F-753726FEEC66Q34405325-89BBC10F-7C3E-4B27-9B26-D72670A6140EQ34426949-F5A81DE7-7870-48FE-B116-E3DD5954BE65Q35149637-314F80BF-DF6F-4372-9B1C-84CAE09300A3Q35506253-B09F8EE0-1FD0-4497-984E-A2687D984FA6Q35594838-EA111257-8E1B-4AD5-B80B-1835B1A07A42Q35653264-57CFDFE5-54DB-4914-8350-9E14B89B9BF1Q36582785-4C920151-192D-4276-9B9F-3045C82564ADQ36664213-86F9BE56-8C6A-4B9E-88D0-39005A96CFDAQ36664224-F2D21C1B-239D-463D-9FFE-4DBF363C0267Q36757131-6A1077BC-9705-4DFA-BD2F-38AB0DE8F77FQ36925337-9F0099B9-D5C3-42EA-9420-BFBE58749D6AQ37028023-CF469E0C-0368-4898-A8FD-958F7387AEA3Q37104963-6A5B4163-1D5C-4422-9847-7CA7CFE9AEAEQ37151620-93E12F24-AABB-4AB8-885B-DD0A682A08D1Q38099680-B6F3F086-6BAC-4935-80B6-9C24AB612B0EQ38120535-E5318703-AE43-4FAD-8231-789D546B10E5Q38151492-66D54B03-F9D6-4F90-A249-F119460D8AB0Q38152474-BF3837A3-2D5D-4AC3-A302-A679661A9943Q38162950-52666909-FBA0-4233-953E-D8A30D22702DQ38295771-0BEDB77E-A6C2-4097-BB12-8052FA5454EBQ38657642-381BC926-9609-43FB-AB5C-4C2E7538E1B2Q38727470-6CE88E27-2FB1-4120-931A-512E79CAD86AQ38765125-35675E1B-23A1-43A7-ADAB-FE976B341F1EQ38845195-2CB4B1AB-96BE-4A1D-9DA2-72F84F91A979Q38848223-D1129758-3DA8-451D-A9CD-AE314B613B20Q38875030-AD616205-4BED-4472-8D97-164BF35C4B7CQ38886593-0373A0B7-C045-4BB5-A31E-24B4C308B9B1Q38974499-1E5FF72E-DD5A-4630-B15E-7FE6FF2C519C
P2860
Oncolytic immunotherapy of advanced solid tumors with a CD40L-expressing replicating adenovirus: assessment of safety and immunologic responses in patients.
description
2012 nî lūn-bûn
@nan
2012年の論文
@ja
2012年学术文章
@wuu
2012年学术文章
@zh
2012年学术文章
@zh-cn
2012年学术文章
@zh-hans
2012年学术文章
@zh-my
2012年学术文章
@zh-sg
2012年學術文章
@yue
2012年學術文章
@zh-hant
name
Oncolytic immunotherapy of adv ...... nologic responses in patients.
@en
Oncolytic immunotherapy of adv ...... nologic responses in patients.
@nl
type
label
Oncolytic immunotherapy of adv ...... nologic responses in patients.
@en
Oncolytic immunotherapy of adv ...... nologic responses in patients.
@nl
prefLabel
Oncolytic immunotherapy of adv ...... nologic responses in patients.
@en
Oncolytic immunotherapy of adv ...... nologic responses in patients.
@nl
P2093
P50
P921
P1433
P1476
Oncolytic immunotherapy of adv ...... nologic responses in patients.
@en
P2093
Aila Karioja-Kallio
Ann M Leen
Elina Haavisto
Kaarina P L Partanen
Kalevi Kairemo
Leena Laasonen
Lotta Kangasniemi
Saila K Pesonen
Sari Pesonen
Satu Kauppinen
P304
P356
10.1158/0008-5472.CAN-11-3001
P407
P577
2012-02-09T00:00:00Z